research use only
Cat.No.S6575
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| HCC1806 | Cytotoxicity assay | 3 days | Cytotoxicity against human HCC1806 cells assessed as reduction in cell viability incubated for 3 days by cell-titer-Glo reagent based assay, IC50 = 6.2 μM. | 26116180 | ||
| HCC38 | Cytotoxicity assay | 3 days | Cytotoxicity against human HCC38 cells assessed as reduction in cell viability incubated for 3 days by cell-titer-Glo reagent based assay, IC50 = 8.7 μM. | 26116180 | ||
| HCC1143 | Cytotoxicity assay | 3 days | Cytotoxicity against human HCC1143 cells assessed as reduction in cell viability incubated for 3 days by cell-titer-Glo reagent based assay, IC50 = 9.5 μM. | 26116180 | ||
| HCC38 | Cytotoxicity assay | 3 days | Cytotoxicity against human HCC38 cells assessed as reduction in cell viability incubated for 3 days by cell-titer-Glo reagent based assay | 26116180 | ||
| HEK293 | Function assay | 10 uM | 24 hrs | Increase in CHOP mRNA expression in HEK293 cells at 10 uM incubated for 24 hrs by qRT-PCR method | 26116180 | |
| HCC1806 | Cytotoxicity assay | 3 days | Cytotoxicity against human HCC1806 cells assessed as reduction in cell viability incubated for 3 days by cell-titer-Glo reagent based assay | 26116180 | ||
| HCC1143 | Cytotoxicity assay | 3 days | Cytotoxicity against human HCC1143 cells assessed as reduction in cell viability incubated for 3 days by cell-titer-Glo reagent based assay | 26116180 | ||
| HEK293T | Function assay | 10 uM | 24 hrs | Increase in CHOP expression in HEK293T cells stably transfected with luciferase gene at 10 uM incubated for 24 hrs by luciferase reporter gene assay | 26116180 | |
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 72 mg/mL
(201.06 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 358.09 | Formula | C11H7IN2O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 314054-00-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=CC=C1NC(=O)C2=CC=C(O2)[N+](=O)[O-])I | ||
| Targets/IC50/Ki |
STING
|
|---|---|
| In vitro |
C-176 strongly reduces STING-mediated, but not RIG-I- or TBK1-mediated, IFNβ reporter activity. It directly targets mouse STING (mmSTING) but not human STING (hsSTING). |
| In vivo |
C-176 attenuates STING-associated autoinflammatory disease in mice. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.